Details for Patent: 7,473,761

Title:	Somatostatin analogues
Abstract:	The invention provides cyclo[{4-(NH.sub.2--C.sub.2H.sub.4--NH--CO--O--)Pro}-Phg-DTrp-Lys-Tyr(4-B- enzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
Inventor(s):	Albert; Rainer (Basel, CH), Bauer; Wilfried (Lampenberg, CH), Bodmer; David (Klingnau, CH), Bruns; Christian (Freiburg, DE), Felner; Ivo (Reinach, CH), Hellstern; Heribert (Heitersheim, DE), Lewis; Ian (Riehen, CH), Meisenbach; Mark (Durmenach, FR), Weckbecker; Gisbert (Biel-Benken, CH), Wietfeld; Bernhard (Efringen-Kirchen, DE)
Assignee:	Novartis AG (Basel, CH)
Filing Date:	Jul 30, 2001
Application Number:	10/343,288
Claims:	1. A compound of formula ##STR00002## where one of the amino groups being optionally in protected form, or a salt or complex thereof. 2. A compound according to claim 1 in unprotected form, in salt form. 3. A compound according to claim 2 as a mono- or disalt. 4. A compound according to claim 3 in the form of an acetate, benzoate, aspartate or pamoate salt. 5. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, in association with one or more pharmaceutically acceptable diluent(s) or carrier(s) therefor. 6. A pharmaceutical composition according to claim 5, in a sustained release form or in a topical form. 7. A pharmaceutical composition according to claim 5, for use in combination with an immunosuppressive agent, an anti-inflammatory agent, a GH secretagogue receptor modulating agent, a GH receptor antagonist, an insulin secretagogue, an insulin secretion enhancer, an insulin sensitizer, a low dose of insulin, an agent having anti-angiogenetic effects or a chemotherapeutic agent. 8. A compound of formula ##STR00003## where one of the amino groups being optionally in protected form, or a salt or complex thereof and R.sup.1 is a chelating agent, optionally complexed with a detectable or a radiotherapeutic element.